"Levodopa" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The naturally occurring form of DIHYDROXYPHENYLALANINE and the immediate precursor of DOPAMINE. Unlike dopamine itself, it can be taken orally and crosses the blood-brain barrier. It is rapidly taken up by dopaminergic neurons and converted to DOPAMINE. It is used for the treatment of PARKINSONIAN DISORDERS and is usually given with agents that inhibit its conversion to dopamine outside of the central nervous system.
| Descriptor ID |
D007980
|
| MeSH Number(s) |
D02.092.311.200.480 D12.125.072.050.685.400.500 D12.125.072.050.875.130.500
|
| Concept/Terms |
Levodopa- Levodopa
- L-Dopa
- L Dopa
- 3-Hydroxy-L-tyrosine
- 3 Hydroxy L tyrosine
- L-3,4-Dihydroxyphenylalanine
- L 3,4 Dihydroxyphenylalanine
|
Below are MeSH descriptors whose meaning is more general than "Levodopa".
Below are MeSH descriptors whose meaning is more specific than "Levodopa".
This graph shows the total number of publications written about "Levodopa" by people in this website by year, and whether "Levodopa" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2009 | 1 | 0 | 1 |
| 2010 | 0 | 1 | 1 |
| 2012 | 0 | 1 | 1 |
| 2016 | 0 | 1 | 1 |
| 2017 | 0 | 1 | 1 |
| 2020 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Levodopa" by people in Profiles.
-
BDNF rs6265 Variant Alters Outcomes with Levodopa in Early-Stage Parkinson's Disease. Neurotherapeutics. 2020 10; 17(4):1785-1795.
-
Comparison of General and Local Anesthesia for Deep Brain Stimulator Insertion: A Systematic Review. Can J Neurol Sci. 2017 11; 44(6):697-704.
-
Flamenco dancer posture: Unique "off" complication in Parkinson disease. Neurology. 2016 04 12; 86(15):1462-1463.
-
Prevention of iron- and copper-mediated DNA damage by catecholamine and amino acid neurotransmitters, L-DOPA, and curcumin: metal binding as a general antioxidant mechanism. Dalton Trans. 2012 Jun 07; 41(21):6458-67.
-
Impairments in social cognition in early medicated and unmedicated Parkinson disease. Cogn Behav Neurol. 2010 Sep; 23(3):152-8.
-
Reducing dosing frequency of carbidopa/levodopa: double-blind crossover study comparing twice-daily bilayer formulation of carbidopa/levodopa (IPX054) versus 4 daily doses of standard carbidopa/levodopa in stable Parkinson disease patients. Clin Neuropharmacol. 2009 Jul-Aug; 32(4):189-92.
-
Anxiety disorders in patients with Parkinson's disease. Am J Psychiatry. 1990 Feb; 147(2):217-20.
-
Transient shortening of estrous cycles in aging C57BL/6J mice: effects of spontaneous pseudopregnancy, progesterone, L-dihydroxyphenylalanine, and hydergine. Biol Reprod. 1987 May; 36(4):949-59.
-
Biological factors in obsessive-compulsive disorders. Psychol Bull. 1985 May; 97(3):430-50.
-
Chemotherapy of malignant melanoma. J Am Acad Dermatol. 1982 Mar; 6(3):412-6.